ASH: Axi-Cel CAR T-Cell Treatment Effective in High-Risk Lymphoma Patients

TUESDAY, Dec. 12, 2023 -- For patients with relapsed or refractory large B-cell lymphoma, including those with comorbidities, the autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy axicabtagene ciloleucel (axi-cel) yields five-year...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news